Abramowitz Yigal, Banai Shmuel, Katz Guy, Steinvil Arie, Arbel Yaron, Havakuk Ofer, Halkin Amir, Ben-Gal Yanai, Keren Gad, Finkelstein Ariel
Department of Cardiology, The Tel-Aviv Medical Center, Tel-Aviv, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Catheter Cardiovasc Interv. 2014 Mar 1;83(4):649-54. doi: 10.1002/ccd.25233. Epub 2013 Oct 31.
To assess the safety and effectiveness of performing percutaneous coronary intervention (PCI) before transcatheter aortic valve implantation (TAVI).
The presence of coronary artery disease (CAD) negatively impact procedural outcomes and long-term survival after (TAVI). The management of obstructive CAD before TAVI is not yet well established.
Patients with severe symptomatic aortic stenosis (AS) (n = 249) that underwent TAVI were divided into two groups: patients with CAD (subdivided to patients treated with TAVI alone and to patients that underwent PCI before TAVI) and patients with isolated AS. Procedural endpoints, device success and adverse events were considered according to the Valve Academic Research Consortium (VARC) definitions.
Of a cohort of 249 consecutive patients with mean age of 83.2 ± 5.5 years, 83 patients with AS + CAD were treated with TAVI alone, 61 patients with AS + CAD underwent PCI before TAVI and 105 patients underwent TAVI for isolated AS. The mean duration of follow-up was 17 months (range: 6-36 months). Despite a significantly higher logistic EuroScore of the AS+CAD group compared to the AS alone group (30.1 vs. 21.1 P < 0. 001), the overall VARC-adjudicated endpoints did not differ between the groups. All-cause mortality at 30-days was 1.6% for patients with AS+CAD treated with PCI compared to 2.9% for patients with AS alone (P = 1).
Performing PCI before TAVI in high-risk elderly patients with significant CAD and severe AS is feasible and safe. This combined treatment approach did not increase the periprocedural risk for complications or the all-cause mortality.
评估在经导管主动脉瓣植入术(TAVI)前进行经皮冠状动脉介入治疗(PCI)的安全性和有效性。
冠状动脉疾病(CAD)的存在对TAVI后的手术结果和长期生存产生负面影响。TAVI前阻塞性CAD的管理尚未完全确立。
将接受TAVI的严重症状性主动脉瓣狭窄(AS)患者(n = 249)分为两组:CAD患者(再细分为仅接受TAVI治疗的患者和在TAVI前接受PCI的患者)和孤立性AS患者。根据瓣膜学术研究联盟(VARC)的定义考虑手术终点、器械成功率和不良事件。
在连续的249例平均年龄为83.2±5.5岁的患者队列中,83例AS + CAD患者仅接受TAVI治疗,61例AS + CAD患者在TAVI前接受PCI,105例患者因孤立性AS接受TAVI。平均随访时间为17个月(范围:6 - 36个月)。尽管AS + CAD组的逻辑欧洲心脏手术风险评估系统(EuroScore)显著高于孤立性AS组(30.1对21.1,P < 0.001),但两组间总体VARC判定的终点并无差异。PCI治疗的AS + CAD患者30天全因死亡率为1.6%,而孤立性AS患者为2.9%(P = 1)。
在患有严重CAD和严重AS的高危老年患者中,在TAVI前进行PCI是可行且安全的。这种联合治疗方法并未增加围手术期并发症风险或全因死亡率。